Foghorn therapeutics presents new preclinical data on selective smarca2 inhibitor fhd-909 and selective cbp and selective ep300 degrader programs and provides pipeline update

- fhd-909 (ly4050784) advancing in phase 1 trial in smarca4 (brg1) mutated cancers, with non-small cell lung cancer (nsclc) as the primary target population
FHTX Ratings Summary
FHTX Quant Ranking